|
sars-cov-2 |
25 |
|
diabetes mellitus |
21 |
|
covid-19 |
20 |
|
hypothyroidism |
19 |
|
hip fractures |
18 |
|
thyroid function tests |
17 |
|
osteoporosis |
13 |
|
thyroid gland |
13 |
|
mortality |
12 |
|
type 2 diabetes mellitus |
12 |
|
autoimmunity |
11 |
|
clinical vertebral fractures |
11 |
|
diabetes |
11 |
|
fatty liver disease |
11 |
|
graves disease |
11 |
|
hyperthyroidism |
11 |
|
long covid |
11 |
|
mafld (metabolic associated fatty liver disease) |
11 |
|
obesity |
11 |
|
osteoporotic fractures |
11 |
|
overweight |
11 |
|
population based study |
11 |
|
sars-cov-2 infection |
11 |
|
thyroid dysfunction |
11 |
|
thyroiditis |
11 |
|
type 2 diabetes |
11 |
|
upper limb fractures |
11 |
|
cardiovascular |
9 |
|
euthyroid sick syndromes |
9 |
|
chinese |
8 |
|
immunotherapy |
8 |
|
interferon beta-1b |
8 |
|
neoplasms |
8 |
|
survival |
8 |
|
thyroid diseases |
8 |
|
type 2 |
8 |
|
autoantibodies |
7 |
|
dpp4 inhibitor |
7 |
|
fib-4 |
7 |
|
glp1 receptor agonists |
7 |
|
metabolic dysfunction–associated steatohepatitis |
7 |
|
nfs |
7 |
|
pioglitazone |
7 |
|
post–acute covid-19 syndrome |
7 |
|
prognosis |
7 |
|
sglt2 inhibitor |
7 |
|
sglt2 inhibitors |
7 |
|
alzheimer's disease |
6 |
|
cardiovascular diseases |
6 |
|
cohort profile // chinese |
6 |
|
crisps |
6 |
|
follow - up care |
6 |
|
glycaemia |
6 |
|
glycated hemoglobin a |
6 |
|
hba1c variability |
6 |
|
hypoglycemia |
6 |
|
metabolic syndrome |
6 |
|
non-alcoholic fatty liver disease |
6 |
|
physician encounters |
6 |
|
postmenopause |
6 |
|
prediction model |
6 |
|
risk stratification |
6 |
|
adipocyte fatty acid-binding protein |
5 |
|
adiponectin |
5 |
|
arthroplasty |
5 |
|
aspirin |
5 |
|
bariatric surgery |
5 |
|
cancer |
5 |
|
continuous glucose monitoring |
5 |
|
diet modification |
5 |
|
dyslipidemia |
5 |
|
elasticity imaging techniques |
5 |
|
endoscopic ultrasound |
5 |
|
fibrosis |
5 |
|
hdl cholesterol |
5 |
|
insulinoma |
5 |
|
microvascular complications |
5 |
|
nephropathy |
5 |
|
non‐invasive |
5 |
|
radio frequency ablation |
5 |
|
risk assessment |
5 |
|
score |
5 |
|
systematic review |
5 |
|
weight loss intervention |
5 |
|
2022 who classification |
4 |
|
aberrant splicing |
4 |
|
acth precursor |
4 |
|
atherosclerotic cardiovascular disease |
4 |
|
atrial fibrillation |
4 |
|
atypical femoral fractures |
4 |
|
bisphosphonates |
4 |
|
bone mineral density |
4 |
|
covid-19 vaccines |
4 |
|
covid‐19 |
4 |
|
cushing’s syndrome |
4 |
|
diabetes mellitus type 1 |
4 |
|
diabetes mellitus, type 2 |
4 |
|
diabetic kidney disease |
4 |
|
dipeptidyl-peptidase iv inhibitors |
4 |
|
dpp4i |
4 |
|
ectopic acth syndrome |
4 |
|
fractures, bone |
4 |
|
gitelman syndrome |
4 |
|
glucagon-like peptide-1 receptor agonists |
4 |
|
glycogenic hepatopathy |
4 |
|
graves' disease |
4 |
|
heart failure |
4 |
|
hip structure analysis |
4 |
|
hospitalization |
4 |
|
hyperinflammatory syndrome |
4 |
|
in-hospital death |
4 |
|
ischemic stroke |
4 |
|
ldl receptor |
4 |
|
liver function tests |
4 |
|
neutrophils |
4 |
|
non-functioning pituitary neuroendocrine tumours |
4 |
|
pancreatic tumor |
4 |
|
pitnet classification |
4 |
|
pituitary adenoma |
4 |
|
slc12a3 |
4 |
|
sodium glucose co-transporter 2 inhibitors |
4 |
|
sodium-glucose cotransporter 2 inhibitors |
4 |
|
sodium-glucose transporter 2 inhibitors |
4 |
|
stroke |
4 |
|
target trial emulation |
4 |
|
trabecular bone score |
4 |
|
transcription factors |
4 |
|
viral clearance |
4 |
|
yolk sac tumor |
4 |
|
adipokine |
3 |
|
apolipoprotein a |
3 |
|
apolipoprotein b |
3 |
|
apolipoprotein e |
3 |
|
cardiovascular disease |
3 |
|
fracture |
3 |
|
glycated haemoglobin a |
3 |
|
graves'disease |
3 |
|
high-density lipoprotein cholesterol |
3 |
|
hong kong |
3 |
|
hypoglycaemia |
3 |
|
inflammation |
3 |
|
interferons |
3 |
|
lipoprotein glomerulopathy |
3 |
|
low-density lipoprotein cholesterol |
3 |
|
nephrotic syndrome |
3 |
|
post-acute covid-19 syndrome |
3 |
|
prehospital care |
3 |
|
proteinuria |
3 |
|
radiofrequency ablation |
3 |
|
radioiodine |
3 |
|
statin |
3 |
|
thyroidectomy |
3 |
|
trauma diversion |
3 |
|
triage |
3 |
|
triglycerides |
3 |
|
ultrasonography |
3 |
|
vaccines |
3 |
|
anti-inflammatory activity |
2 |
|
anti-oxidative activity |
2 |
|
c-peptide |
2 |
|
cascade screening |
2 |
|
cholesterol efflux |
2 |
|
familial hypercholesterolemia |
2 |
|
fibroblast growth factor-21 |
2 |
|
genetic testing |
2 |
|
insulin resistance |
2 |
|
insulin secretion |
2 |
|
intracellular lipid |
2 |
|
monocytes |
2 |
|
(mesh): obesity |
1 |
|
acute coronary syndrome |
1 |
|
asian |
1 |
|
body weight |
1 |
|
bone |
1 |
|
bupropion hydrochloride |
1 |
|
clopidogrel |
1 |
|
east asian people |
1 |
|
fractures |
1 |
|
naltrexone hydrochoride drug combination |
1 |
|
percutaneous coronary intervention |
1 |
|
ticagrelor |
1 |
